ImmunoGen, Inc. (IMGN) Financial Statements (2024 and earlier)

Company Profile

Business Address 830 WINTER ST
WALTHAM, MA 02451
State of Incorp. MA
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments275,138478,750293,856176,225262,252267,107
Cash and cash equivalents275,138478,750293,856176,225262,252267,107
Receivables13,8146,812468,5012,3185,229
Inventory, net of allowances, customer advances and progress billings     1,038
Inventory     1,038
Other undisclosed current assets15,16914,43730,35224,17214,2112,967
Total current assets:304,121499,999324,254208,898278,781276,341
Noncurrent Assets
Inventory, Noncurrent16,196     
Operating lease, right-of-use asset10,23112,39214,07215,587
Property, plant and equipment4,3774,6635,7606,99312,89114,538
Other noncurrent assets14,0118,71110,9863,7843,7093,797
Total noncurrent assets:44,81525,76630,81826,36416,60018,335
TOTAL ASSETS:348,936525,765355,072235,262295,381294,676
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities95,24746,98043,47832,85644,46336,586
Employee-related liabilities5,4694,6208,99111,79611,473
Accounts payable45,35318,4349,5389,93311,3658,562
Accrued liabilities49,89423,07729,32013,93221,30216,551
Deferred revenue13,85644,35129,249309
Debt   2,0932,971  
Deferred revenue and credits1,405
Contract with customer, liability317
Other undisclosed current liabilities12,7559,61447,50341,27425,88017,779
Total current liabilities:121,858100,945122,32377,41070,66055,770
Noncurrent Liabilities
Long-term debt and lease obligation  15,24418,65123,8762,0642,050
Long-term debt, excluding current maturities    2,0782,0642,050
Liabilities, other than long-term debt47,80349,02383,446127,83084,665103,117
Deferred revenue and credits98,881
Deferred revenue36,35547,71780,860127,123
Contract with customer, liability80,485
Other liabilities3001,3062,5867074,1804,236
Operating lease, liability11,14815,24418,65121,798
Other undisclosed noncurrent liabilities23,44934,96741,08282,267127,020151,634
Total noncurrent liabilities:71,25299,234143,179233,973213,749256,801
Total liabilities:193,110200,179265,502311,383284,409312,571
Equity
Equity, attributable to parent155,826325,58689,570(76,121)10,972(17,895)
Common stock2,2602,2041,9501,5011,4941,325
Additional paid in capital1,847,6381,794,5251,419,4601,209,8461,192,8131,009,362
Accumulated deficit(1,694,072)(1,471,143)(1,331,840)(1,287,468)(1,183,335)(1,028,582)
Total equity:155,826325,58689,570(76,121)10,972(17,895)
TOTAL LIABILITIES AND EQUITY:348,936525,765355,072235,262295,381294,676

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues108,78269,856132,29982,27153,446115,447
Cost of revenue
(Cost of Goods and Services Sold)
      (1,100)
Gross profit:108,78269,856132,29982,27153,446114,347
Operating expenses(329,675)(194,929)(154,679)(174,444)(214,895)(174,429)
Other undisclosed operating income      1,100
Operating loss:(220,893)(125,073)(22,380)(92,173)(161,449)(58,982)
Nonoperating income (expense)3,347(1,080)1,2105,0143,3322,607
Investment income, nonoperating4,341517294,4244,2271,146
Other nonoperating income (expense)(994)(1,131)481590(895)1,461
Interest and debt expense (47)(95)(95)(95)(25,955)
Loss from continuing operations before equity method investments, income taxes:(217,546)(126,200)(21,265)(87,254)(158,212)(82,330)
Other undisclosed loss from continuing operations before income taxes(4,165)(13,103)(23,107)(16,879)(10,631)(13,682)
Loss from continuing operations before income taxes:(221,711)(139,303)(44,372)(104,133)(168,843)(96,012)
Income tax expense (benefit)(1,218)     
Other undisclosed loss from continuing operations      
Loss from continuing operations:(222,929)(139,303)(44,372)(104,133)(168,843)(96,012)
Loss before gain (loss) on sale of properties:(139,303)(44,372)(104,133)(168,843)(96,012)
Other undisclosed net income      
Net loss attributable to parent:(222,929)(139,303)(44,372)(104,133)(168,843)(96,012)
Other undisclosed net loss available to common stockholders, basic      
Net loss available to common stockholders, diluted:(222,929)(139,303)(44,372)(104,133)(168,843)(96,012)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(222,929)(139,303)(44,372)(104,133)(168,843)(96,012)
Comprehensive loss, net of tax, attributable to parent:(222,929)(139,303)(44,372)(104,133)(168,843)(96,012)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: